Singh G Dave, Kherani Shamshudin
Institute of Craniofacial Sleep Medicine, Vivos Therapeutics, Inc., Highlands Ranch, CO 80129, United States.
Dental Clinic, Kherani Dental at Aspen, Calgary T3H0N6, Canada.
World J Clin Cases. 2021 Apr 6;9(10):2312-2319. doi: 10.12998/wjcc.v9.i10.2312.
Mandibular advancement devices (MADs) are used to treat mild to moderate obstructive sleep apnea (OSA), but there is a risk that the underlying condition can worsen in the long-term. Therefore, this case report is based on biomimetic oral appliance therapy as an alternative to MADs, which was found to be beneficial in the treatment of a case with severe OSA.
An overnight sleep study was undertaken in a 50-year-old male with excessive daytime sleepiness that lead to a diagnosis of severe OSA as the apnea-hypopnea index (AHI) was found to be 32.8/h. Since the patient was unable to comply with continuous positive airway pressure therapy and declined surgical intervention, treatment with a MAD was initiated. Approximately 10 years later, another sleep study was performed with no MAD in the mouth, which revealed an AHI of 67.9/h. In view of the deterioration in sleep quality, the patient sought alternative treatment and elected on biomimetic oral appliance therapy, using a mandibular repositioning nighttime appliance (mRNA appliance, Vivos Therapeutics, Inc., United States). After 10 mo, another sleep study was performed with no device in the patient's mouth, which revealed an AHI of 11.8/h, a mean oxygen saturation of 94% and a mean oxygen desaturation index of 5.3% while sleeping. Finite-element analysis of the pre- and post-treatment study models of the upper jaw showed localized size increases of 15%-17% in the premolar regions and 15%-23% in the molar regions.
In adults with severe OSA that are unable to accept continuous positive airway pressure or surgical treatment, biomimetic oral appliance therapy may be preferable over MADs since biomimetic oral appliance therapy may be able to prevent worsening of sleep parameters by remodeling the nasomaxillary complex. Long-term follow up studies are required to verify these novel findings.
下颌前移装置(MADs)用于治疗轻至中度阻塞性睡眠呼吸暂停(OSA),但长期来看存在病情加重的风险。因此,本病例报告基于仿生口腔矫治器疗法作为MADs的替代方法,该方法在治疗一例重度OSA患者中被发现有益。
对一名50岁男性进行了夜间睡眠研究,该男性白天过度嗜睡,经检查发现呼吸暂停低通气指数(AHI)为32.8次/小时,诊断为重度OSA。由于患者无法耐受持续气道正压通气治疗且拒绝手术干预,遂开始使用MADs进行治疗。大约10年后,在未佩戴MADs的情况下进行了另一项睡眠研究,结果显示AHI为67.9次/小时。鉴于睡眠质量恶化,患者寻求替代治疗并选择了仿生口腔矫治器疗法,使用下颌重新定位夜间矫治器(mRNA矫治器,美国Vivos Therapeutics公司)。10个月后,在患者未佩戴装置的情况下进行了另一项睡眠研究,结果显示睡眠时AHI为11.8次/小时,平均血氧饱和度为94%,平均氧饱和度下降指数为5.3%。对上颌治疗前后研究模型的有限元分析显示,前磨牙区域局部尺寸增加了15%-17%,磨牙区域增加了15%-23%。
对于无法接受持续气道正压通气或手术治疗的重度OSA成年患者,仿生口腔矫治器疗法可能比MADs更可取,因为仿生口腔矫治器疗法可能能够通过重塑鼻上颌复合体来防止睡眠参数恶化。需要进行长期随访研究以验证这些新发现。